F. Gheyas

发表

Microarray profile of differentially expressed genes in a monkey model of allergic asthma

Jun Zou, Simon Young, Feng Zhu, 2002, Genome Biology.

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression

Luquan Wang, Beth Hutchins, Ferdous Gheyas, 2003, Oncogene.

Human members of the eukaryotic protein kinase family

Luquan Wang, Ferdous Gheyas, F. Gheyas, 2002, Genome Biology.

Operating characteristics of stepwise covariate selection in pharmacometric modeling

Casey B. Davis, F. Gheyas, P. Diderichsen, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects

F. Gheyas, Yang Liu, R. Krishna, 2021, Advances in Therapy.

Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects

Yang Liu, F. Gheyas, J. Wagner, 2018, Journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects

F. Gheyas, O. Laterza, J. Wagner, 2018, Journal of clinical pharmacology.

Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination

F. Gheyas, R. Krishna, D. Gutstein, 2017, Clinical pharmacology and therapeutics.

Mouse ADAM33: two splice variants differ in protein maturation and localization.

F. Gheyas, Y. Wan, S. Umland, 2004, American journal of respiratory cell and molecular biology.

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

F. Gheyas, D. Hilbert, F. Bellanti, 2021, Clinical and translational science.

Dietary fibre composition in developing apple fruits

F. Gheyas, R. F. Mcfeeters, S. Blankenship, 1998 .

Identification of differentially expressed genes in a monkey model of allergic asthma by microarray technology.

Jun Zou, Simon Young, Feng Zhu, 2002, Chest.

Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis

F. Gheyas, P. Armstrong, R. Blaustein, 2022, Clinical pharmacology and therapeutics.

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

N. Butkiewicz, F. Gheyas, X. Tong, 2006, Antimicrobial Agents and Chemotherapy.

Formulation and process considerations for beads containing Carbopol 974P, NF resin made by extrusion-spheronization.

F Gheyas, F. Gheyas, S. Neau, 2000, International journal of pharmaceutics.

Dietary fibre content of thirteen apple cultivars

F. Gheyas, R. F. Mcfeeters, S. Blankenship, 1997 .

Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients.

F. Gheyas, J. Levy, V. Soumelis, 2001, Blood.

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects

F. Gheyas, S. Nagalla, R. Wrishko, 2016, Clinical and translational science.

Analysis of the ERK1,2 transcriptome in mammary epithelial cells.

F. Gheyas, Luquan Wang, Wei Ding, 2004, The Biochemical journal.

Leveraging model-informed approaches for drug discovery and development in the cardiovascular space

Manash S. Chatterjee, Ferdous Gheyas, Marissa F Dockendorf, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice

F. Gheyas, D. Johns, Sanjeev Kumar, 2016, Drug Metabolism and Disposition.

Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma

F. Gheyas, E. Chartash, D. Alwis, 2021, Clinical Trials.

Composite method to quantify powder flow as a screening method in early tablet or capsule formulation development

Michael K. Taylor, F. Gheyas, A. Hickey, 2000, AAPS PharmSciTech.

A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data

F. Gheyas, M. Wiener, J. Sachs, 2021, NPJ vaccines.

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation

F. Gheyas, G. Stebbins, K. Marek, 2021, Clinical pharmacology and therapeutics.

Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group

C M Bromley, S Close, N Cohen, 2009, The Pharmacogenomics Journal.

Interferon in Replicon Cells Enhances the Antiviral Activity of Alpha Suppresses Polyprotein Maturation and of Hepatitis C Virus NS 3 Protease , SCH 503034 , a Mechanism-Based Inhibitor

F. Gheyas, X. Tong, C. Jiang, 2005 .

SAMPLING STRATEGIES FOR DETECTING RARE IMPURITIES: AN APPLICATION IN GENE THERAPY PRODUCTS

Chen Wang, Ferdous Gheyas, F. Gheyas, 2005, Journal of biopharmaceutical statistics.

Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.

F. Gheyas, A. Dosne, Kunal S. Taskar, 2024, Clinical pharmacology and therapeutics.

Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science

F. Gheyas, Maria E Trujillo, Surya Ayalasomayajula, 2023, Clinical and translational science.